ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Trial details
- Registry ID
- NCT07007559
- Phase
- Phase 2
The FDA approved Eribulin (Halaven) on 15 Nov 2010.
Drug identity checked against registry records
Also recorded as Halaven
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast CancerNCT07007559 | ALX Oncology Inc. | Phase 2 | Recruiting | 2027-12Estimated |
| A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast CancerNCT06435429 | Jazz Pharmaceuticals | Phase 3 | Recruiting | 2028-04-28Estimated |
| A Study to Investigate Efficacy & Safety of Intratumoral INT230-6 Compared to US Standard of Care in Adults With Soft Tissue Sarcomas (INVINCIBLE-3)NCT06263231 | INTS | Phase 3 | Recruiting | 2027-12Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2010-11-15Day | Eribulin | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA201532", "applicant_as_listed_by_fda": "EISAI INC", "brand_names": ["HALAVEN"], "active_ingredients": ["ERIBULIN MESYLATE"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20101115", "matched_on": "registry alias equals FDA brand name and drug name is its active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |